Shorter trial authorisation timelines for ATMP trials in the US are an advantage for biotechs, say experts. Although the ...

Ladenburg, Germany, 21 March 2025 – Heidelberg Pharma AG (FSE: HPHA) today published its financial results and Annual Report for fiscal year 2024 (1 December 2023 – 30 November 2024) and its outlook ...

Precigen (PGEN) reported better-than-expected first-quarter earnings and is making strides toward commercializing its lead ...

Laromestrocel (Lomecel-B™) has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Alzheimer’s disease which provides frequent interactions with the FDA, intensive guidance on ...

LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) is a company that should be getting more attention from investors and the just released annual results again proved that point. LGVN ...